Eleven therapies, including five targeting rare diseases, have taken a giant leap towards being approved in Europe after winning backing from the European Medicines Agency’s Committee for Medicinal Products for Human Use.
UCB has secured an important win for the protection of its anti-epileptic Vimpat in the US this week after the Delaware District Court confirmed the validity of a key patent for the drug.